137 related articles for article (PubMed ID: 17483764)
1. [Symptomatic hypokalemia caused by meglumine antimoniate].
Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
[No Abstract] [Full Text] [Related]
2. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
Marsden PD
Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
[No Abstract] [Full Text] [Related]
3. [Meglumine antimoniate].
Silva JB
Rev Soc Bras Med Trop; 2001; 34(1):103-5. PubMed ID: 11340506
[No Abstract] [Full Text] [Related]
4. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
[TBL] [Abstract][Full Text] [Related]
5. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
López L; Robayo M; Vargas M; Vélez ID
Trials; 2012 May; 13():58. PubMed ID: 22594858
[TBL] [Abstract][Full Text] [Related]
6. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
Castro C; Sampaio RN; Marsden PD
Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
[No Abstract] [Full Text] [Related]
7. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
[TBL] [Abstract][Full Text] [Related]
8. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
[TBL] [Abstract][Full Text] [Related]
9. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
Lambertucci JR; França BM; Queiroz Ede M
Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
[No Abstract] [Full Text] [Related]
10. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
11. [Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case].
Cucé LC; Belda Júnior W; Dias MC
Rev Inst Med Trop Sao Paulo; 1990; 32(4):249-51. PubMed ID: 2101518
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
13. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
14. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Slappendel RJ; Teske E
Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422
[TBL] [Abstract][Full Text] [Related]
17. Intrarectal glucantime.
Marsden PD
Rev Soc Bras Med Trop; 1996; 29(3):295. PubMed ID: 8701055
[No Abstract] [Full Text] [Related]
18. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable.
de Oliveira-Neto MP; Mattos Mda S
Rev Soc Bras Med Trop; 2006; 39(4):323-6. PubMed ID: 17119744
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment.
Neumayr AL; Walter C; Stoeckle M; Braendle N; Glatz K; Blum JA
J Travel Med; 2012; 19(2):124-6. PubMed ID: 22414039
[TBL] [Abstract][Full Text] [Related]
20. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Aste N; Pau M; Ferreli C; Biggio P
Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
[No Abstract] [Full Text] [Related]
[Next] [New Search]
